Cargando…
The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells
Glioblastoma is one of the most common malignant tumors in the nervous system in both adult and pediatric patients. Studies suggest that abnormal activation of receptor tyrosine kinases contributes to pathological development of glioblastoma. However, current therapies targeting tyrosine kinase rece...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4218911/ https://www.ncbi.nlm.nih.gov/pubmed/25378936 http://dx.doi.org/10.2147/OTT.S67556 |
_version_ | 1782342495666962432 |
---|---|
author | Zhang, Junxia Zhou, Qiang Gao, Ge Wang, Yanfen Fang, Zhihui Li, Guanlin Yu, Mengfei Kong, Lingfei Xing, Ying Gao, Xiaoqun |
author_facet | Zhang, Junxia Zhou, Qiang Gao, Ge Wang, Yanfen Fang, Zhihui Li, Guanlin Yu, Mengfei Kong, Lingfei Xing, Ying Gao, Xiaoqun |
author_sort | Zhang, Junxia |
collection | PubMed |
description | Glioblastoma is one of the most common malignant tumors in the nervous system in both adult and pediatric patients. Studies suggest that abnormal activation of receptor tyrosine kinases contributes to pathological development of glioblastoma. However, current therapies targeting tyrosine kinase receptors have poor therapeutic outcomes. Here, we examined anticancer effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, on glioblastoma cells both in the U87MG cell line and in the mouse xenograft model. We showed that ponatinib treatment reduced cell viability and induced cell apoptosis in a dose-dependent manner in U87MG cells. In addition, ponatinib suppressed migration and invasion of U87MG cells effectively. Furthermore, ponatinib-treated tumors showed an obvious reduction of tumor volume and an increase of apoptosis as compared with vehicle-treated tumors in the mouse xenograft model. These findings support a potential application of ponatinib as a chemotherapeutic option against glioblastoma cells. |
format | Online Article Text |
id | pubmed-4218911 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-42189112014-11-06 The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells Zhang, Junxia Zhou, Qiang Gao, Ge Wang, Yanfen Fang, Zhihui Li, Guanlin Yu, Mengfei Kong, Lingfei Xing, Ying Gao, Xiaoqun Onco Targets Ther Original Research Glioblastoma is one of the most common malignant tumors in the nervous system in both adult and pediatric patients. Studies suggest that abnormal activation of receptor tyrosine kinases contributes to pathological development of glioblastoma. However, current therapies targeting tyrosine kinase receptors have poor therapeutic outcomes. Here, we examined anticancer effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, on glioblastoma cells both in the U87MG cell line and in the mouse xenograft model. We showed that ponatinib treatment reduced cell viability and induced cell apoptosis in a dose-dependent manner in U87MG cells. In addition, ponatinib suppressed migration and invasion of U87MG cells effectively. Furthermore, ponatinib-treated tumors showed an obvious reduction of tumor volume and an increase of apoptosis as compared with vehicle-treated tumors in the mouse xenograft model. These findings support a potential application of ponatinib as a chemotherapeutic option against glioblastoma cells. Dove Medical Press 2014-10-30 /pmc/articles/PMC4218911/ /pubmed/25378936 http://dx.doi.org/10.2147/OTT.S67556 Text en © 2014 Zhang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Zhang, Junxia Zhou, Qiang Gao, Ge Wang, Yanfen Fang, Zhihui Li, Guanlin Yu, Mengfei Kong, Lingfei Xing, Ying Gao, Xiaoqun The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells |
title | The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells |
title_full | The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells |
title_fullStr | The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells |
title_full_unstemmed | The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells |
title_short | The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells |
title_sort | effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human u87 malignant glioblastoma cells |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4218911/ https://www.ncbi.nlm.nih.gov/pubmed/25378936 http://dx.doi.org/10.2147/OTT.S67556 |
work_keys_str_mv | AT zhangjunxia theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT zhouqiang theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT gaoge theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT wangyanfen theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT fangzhihui theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT liguanlin theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT yumengfei theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT konglingfei theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT xingying theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT gaoxiaoqun theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT zhangjunxia effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT zhouqiang effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT gaoge effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT wangyanfen effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT fangzhihui effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT liguanlin effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT yumengfei effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT konglingfei effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT xingying effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells AT gaoxiaoqun effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells |